1- Monday Infectious Disease News – 12th April

1 – Germany restricts use of AstraZeneca vaccine to over 60s in most cases

• German Health Minister Jens Spahn and the 16 state health ministers on Tuesday decided to suspend the routine use of the AstraZeneca vaccine for people under age 60 at an emergency meeting.
• People under 60 can still receive the shot, but only “at the discretion of doctors, and after individual risk analysis and thorough explanation,” according to a document seen by the DPA news agency.
• The decision came amid fresh concern over unusual blood clots reported in a tiny number of younger people who received the vaccine.
• The positive message is that the vaccine from AstraZeneca should continue to be vaccinated for people who have reached the age of 60.

Source: DW News

2 – Holland joins countries putting a halt on AstraZeneca vaccine

• The Netherlands has joined a fast-growing list of countries suspending use of AstraZeneca’s COVID-19 vaccine after reports of unexpected possible side-effects from the injection.
• The vaccine will not be used until at least March 29 as a precaution
• The decision by health authorities in the Netherlands follows a similar decision by Ireland and is based on reports from Denmark and Norway of possible serious side effects.
• Three health workers in Norway who had recently received the vaccine were being treated in hospital for bleeding, blood clots and a low count of blood platelets, Norwegian health authorities said.

Source: Financial Reviews

3 – Evaluating the safety and effectiveness of a nurse-led outpatient virtual IV vancomycin monitoring clinic: a retrospective cohort study

• Outpatient parenteral antimicrobial therapy (OPAT) with vancomycin is a common treatment modality for certain Gram-positive infections.
• Data regarding the safety of various models of delivery are limited.
• This study aims to review outcomes of a nurse-led OPAT vancomycin monitoring service.
• A nurse-led VVC was a safe, effective and inexpensive modality for administering outpatient vancomycin.

Source: Oxford Academic

4- Short-term increase in the carriage of azithromycin-resistant Escherichia coli and Klebsiella pneumoniae in mothers and their newborns following intra-partum azithromycin: a post hoc analysis of a double-blind randomized trial

• This study aims to evaluate the impact of one oral dose of intrapartum azithromycin (2 g) on the carriage and antibiotic resistance of Escherichia coli and Klebsiella pneumoniae in the nasopharynx, breast milk and vaginal swabs of mothers and K. pneumoniae in the nasopharynx of their newborns.
• Oral intrapartum azithromycin did not reduce carriage of E. coli and K. pneumoniae and was associated with an increase in the prevalence of azithromycin-resistant E. coli and K. pneumoniae isolates in BM and VS.

Source: Oxford Academic

5 – Supervised machine learning to support the diagnosis of bacterial infection in the context of COVID-19

• Bacterial infection has been challenging to diagnose in patients with COVID-19.
• They developed and evaluated supervised machine learning algorithms to support the diagnosis of secondary bacterial infection in hospitalized patients during the COVID-19 pandemic.
• An SVM using 21 routine blood test variables had excellent performance at inferring the likelihood of positive microbiology.
• Further prospective evaluation of the algorithms ability to support decision making for the diagnosis of bacterial infection in COVID-19 cohorts is underway.

Source: Oxford Academic

6 – Feasibility study of hospital antimicrobial stewardship analytics using electronic health records

• Hospital antimicrobial stewardship (AMS) programmes are multidisciplinary initiatives to optimize antimicrobial use.
• Most hospitals depend on time-consuming manual audits to monitor clinicians’ prescribing. But much of the information needed could be sourced from electronic health records (EHRs).
• This study aims to develop an informatics methodology to analyse characteristics of hospital AMS practice using routine electronic prescribing and laboratory records.

Source: Oxford Academic

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2021 Antimicrobial Resistance E-News (FNN) Daily Emails?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2020 Antimicrobial Resistance E-News (FNN), for daily publication of Daily News

Read & Download FNN Issue 8 of April 2020 FNN News